

April 24, 2019



Kane Biotech Announces New Sales Representation by SLA Brands

WINNIPEG, Manitoba, April 24, 2019 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the "Corporation" or "Kane Biotech"), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, today announces a strategic partnership with Schiaffino, Lasky, & Associates Inc. (SLA Brands). SLA Brands will exclusively represent Kane Biotech's bluestem line of products to distributors and retailers in the United States (US) market.

"We are extremely pleased to be working with such a well-respected group within the pet industry and look forward expanding the retail footprint of our bluestem line of products across the US market," said Marc Edwards, Kane Biotech's CEO. "We've seen tremendous growth in this line of products over the past few months and expect SLA's representation in a key market to further accelerate our market expansion."

"We look forward to representing Kane Biotech's innovative product line in the US. As one of the most comprehensive pet oral care lines on the market, we anticipate strong sales of Kane's bluestem products," said Bill Schiaffino, Founder and President, SLA Brands, Inc.

About Kane Biotech

Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Corporation has a portfolio of biotechnologies, intellectual property (66 patents and patents pending, trade secrets and trademarks) and products developed by the Corporation's own biofilm research expertise and acquired from leading research institutions. StrixNB(TM), DispersinB(R), Aledex(R), bluestem(TM), AloSera(TM), coactiv+(TM) and Kane(R) are trademarks of Kane Biotech Inc. The Corporation is listed on the TSX Venture Exchange under the symbol "KNE".

For more information, please visit
www.kanebiotech.com or contact:

Marc Edwards
Chief Executive Officer
Kane Biotech Inc.
+1 (514) 910-6991

medwards@kanebiotech.com

Grant Humphrey
Vice President, Sales and Business
Development
Kane Biotech Inc.
+1 (204) 914-5089

ghumphrey@kanebiotech.com

Joe Green
US. Investor Relations
Edison Inc.
+1 (646) 653-7030

jgreen@edisongroup.com

Caution Regarding Forward-Looking Information

This press release contains certain statements regarding Kane Biotech Inc. that constitute forward-looking information under applicable securities law. These statements reflect management's current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks relating to the Company's: (a) financial condition, including lack of significant revenues to date and reliance on equity and other financing; (b) business, including its early stage of development, government regulation, market acceptance for its products, rapid technological change and dependence on key personnel; (c) intellectual property including the ability of the Company to protect its intellectual property and dependence on its strategic partners; and (d) capital structure, including its lack of dividends on its common shares, volatility of the market price of its common shares and public company costs. Further information about these and other risks and uncertainties can be found in the disclosure documents filed by the Company with applicable securities regulatory authorities, available at www.sedar.com. The Company cautions that the foregoing list of factors that may affect future results is not exhaustive.



Source: Kane Biotech Inc.